UPDATED Apr 30, 2024
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$781.10 | 4.7% | 93.2% | US$703.6b | US$823.82 | PE134.3x | E27.2% | 0.7% | Pharmaceuticals & Biotech | ||
UNH | US$483.70 | -0.5% | -2.0% | US$445.0b | US$567.36 | PE29x | E19.2% | 1.6% | Healthcare | ||
JNJ | US$144.59 | -3.3% | -12.4% | US$348.4b | US$173.60 | PE18.2x | E5.1% | 3.4% | Pharmaceuticals & Biotech | ||
MRK | US$129.22 | 1.8% | 9.6% | US$327.3b | US$140.93 | PE141.9x | E26.1% | 2.4% | Pharmaceuticals & Biotech | ||
ABBV | US$162.64 | -4.1% | 7.3% | US$288.0b | US$182.65 | PE48.4x | E23.2% | 3.8% | Pharmaceuticals & Biotech | ||
AZN | UK£120.62 | 7.0% | 2.4% | UK£187.0b | UK£131.45 | PE36.9x | E16.6% | 2.1% | Pharmaceuticals & Biotech | ||
TMO | US$568.72 | -1.0% | 4.6% | US$217.1b | US$620.33 | PE36x | E12.0% | 0.3% | Pharmaceuticals & Biotech | ||
ABT | US$105.97 | -1.5% | -5.0% | US$183.9b | US$126.33 | PE32.8x | E11.3% | 2.1% | Healthcare | ||
DHR | US$246.62 | -2.6% | 1.6% | US$182.7b | US$269.86 | PE44.9x | E13.5% | 0.4% | Pharmaceuticals & Biotech | ||
AMGN | US$273.94 | 0.1% | 16.1% | US$146.9b | US$303.26 | PE21.9x | E9.0% | 3.3% | Pharmaceuticals & Biotech | ||
PFE | US$25.62 | -2.7% | -34.4% | US$145.1b | US$31.62 | PE68x | E20.8% | 6.6% | Pharmaceuticals & Biotech | ||
ISRG | US$370.62 | -1.7% | 23.0% | US$131.5b | US$420.59 | PE66.1x | E11.6% | n/a | Healthcare | ||
SYK | US$336.50 | 0.5% | 14.5% | US$128.0b | US$365.69 | PE40.4x | E12.7% | 1.0% | Healthcare | ||
ELV | US$528.58 | -0.8% | 13.4% | US$122.9b | US$599.48 | PE19.7x | E12.5% | 1.2% | Healthcare | ||
MDT | US$80.24 | -1.3% | -11.1% | US$106.5b | US$94.75 | PE25.4x | E9.7% | 3.4% | Healthcare | ||
BSX | US$71.87 | 4.2% | 35.9% | US$105.6b | US$80.66 | PE59.9x | E18.2% | n/a | Healthcare | ||
VRTX | US$392.81 | -3.0% | 13.5% | US$101.5b | US$459.72 | PE28x | E11.4% | n/a | Pharmaceuticals & Biotech | ||
CI | US$357.04 | 1.2% | 42.6% | US$101.3b | US$381.44 | PE19.6x | E9.6% | 1.6% | Healthcare | ||
REGN | US$890.66 | -1.8% | 11.5% | US$96.1b | US$1,038.08 | PE24.3x | E11.2% | n/a | Pharmaceuticals & Biotech | ||
BMY | US$43.94 | -10.3% | -35.5% | US$89.1b | US$53.76 | PS2x | E43.0% | 5.5% | Pharmaceuticals & Biotech | ||
CSL | AU$276.76 | -0.8% | -8.3% | AU$133.7b | AU$305.37 | PE35.3x | E14.7% | 1.3% | Pharmaceuticals & Biotech | ||
GSK | UK£16.73 | 1.3% | 15.0% | UK£68.4b | UK£20.06 | PE13.9x | E9.3% | 3.5% | Pharmaceuticals & Biotech | ||
CVS | US$67.71 | -1.2% | -6.9% | US$85.3b | US$87.96 | PE10.2x | E6.8% | 3.9% | Healthcare | ||
HCA | US$309.82 | -3.0% | 10.4% | US$81.9b | US$343.58 | PE15x | E6.0% | 0.9% | Healthcare |